12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Company News  |  Deals

Medicis, Revance deal

Medicis returned exclusive, worldwide rights to Revance to develop and commercialize its RT002, an injectable formulation of botulinum toxin type A that uses Revance's TransMTS peptide delivery technology. Medicis also returned an option to license U.S. rights to RT001 for aesthetic indications. RT001 is a topical gel...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >